Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Kate L MahonSarah Im SutherlandHui Ming LinMartin R StocklerHoward GurneyGirish MallesaraKaren BriscoeGavin MarxCelestia S HiganoJohann S de BonoKim N ChiGeorgina ClarkSamuel N BreitDavid A BrownLisa G HorvathPublished in: The Prostate (2024)
Elevated circulating GDF15 is associated with poor prognosis in men with mCRPC receiving docetaxel and may be a marker of changes in the innate immune system in response to docetaxel resistance. These findings provide a strong rationale to consider GDF15 as a biomarker to guide a therapeutic trial of drugs targeting the innate immune system in combination with docetaxel in mCRPC.